

Please insert --Xaa<sup>29</sup>,Xaa<sup>30</sup>-- in the peptide sequence located on page 16, line 25, as indicated in Appendix A. The amended sequence will then read as follows:

Ac-[Glu<sup>8</sup>,Lys<sup>12</sup>,Nle<sup>17</sup>,Val<sup>26</sup>,Thr<sup>28</sup>,Xaa<sup>29</sup>,Xaa<sup>30</sup>,Phe<sup>31</sup>]-VIP (SEQ. ID. NO.: 64);

Please assign --SEQ. ID. NO.: 124-- to the peptide sequence located on page 19, line 9, as indicated in Appendix A. The amended sequence will then read as follows:

[Arg<sup>16</sup>]-VIP (SEQ. ID. NO.: 124);

Please assign --SEQ. ID. NO.: 206-- to the peptide sequence located in the paragraph beginning at line 12, page 28, as indicated in Appendix A. The amended paragraph will then read as follows:

Additional secondary agents useful herein are peptide analogs of  $\alpha$ -melanocyte-stimulating hormone ( $\alpha$ -MSH), also referred to as "melanocortin peptides." Such peptides include the sequence His-Phe-Arg-Trp (SEQ. ID. NO.: 206), His-D-Phe-Arg-Trp, or are homologs thereof, and are preferably cyclic. A preferred melanocortin peptide is Ac-Nle-cyclo-(-Asp-His-D-Phe-Arg-Trp-Lys)-OH. See U.S. Patent No. 6,051,555 to Hadley and International Patent Publication No. WO 01/00224 to Blood et al., assigned to Palatin Technologies, Inc. The aforementioned amino acid residues have their conventional meaning as given in Chapter 2422 of the *Manual of Patent Examining Procedure* (2000). Thus, "Arg" is arginine, "Nle" is norleucine, "His" is histamine, "Phe" is phenylalanine, "D-Phe" is D-phenylalanine, "Trp" is tryptophan, and "Ac" refers to an acetyl moiety, i.e., an acetyl moiety present in a peptide or amino acid sequence that is acetylated.

Please insert the Sequence Listing (attached as Appendix B) after page 48 and before the claims. Please renumber the specification as necessary.